Recurrent deep vein thrombosis despite warfarin therapy in a patient with Crohn's disease

Postgraduate Medicine

Volumn 122, Issue 3, 2010, Pages 181-184

  Lopez, Pablo R ^a   Stewart, David W ^b   Smalligan, Roger D ^c  

^a East Tennessee State University   (United States)

^b EAST TENNESSEE STATE UNIVERSITY   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Anticoagulation; Crohn's disease; Deep vein thrombosis; Inflammatory bowel disease; Pulmonary embolism; Venous thromboembolism; Warfarin

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT;

AGED; ANTICOAGULANT THERAPY; CASE REPORT; CROHN DISEASE; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LEG PAIN; LEG SWELLING; LEG THROMBOSIS; LUNG EMBOLISM; RECURRENT DISEASE; REVIEW; VENA CAVA FILTER; WALKING DIFFICULTY; ARTICLE; VEIN THROMBOSIS;

AGED; ANTICOAGULANTS; CROHN DISEASE; FEMALE; HUMANS; PULMONARY EMBOLISM; RECURRENCE; VENA CAVA FILTERS; VENOUS THROMBOSIS; WARFARIN;

EID: 77953096643     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.05.2155     Document Type: Review

References (28)

1. Magro F, Dinis-Ribeiro M, Araujo F, et al. High prevalence of combined thrombophilic abnormalities in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2003;15(11):1157-1163.
2. Koutroubakis I. Therapy insight: vascular complications in patients with inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol. 2005;2(6):266-272.
3. Aichbichler B, Petritsch W, Reicht G, et al. Anti-cardiolipin antibodies in patients with inflammatory bowel disease. Dig Dis Sci. 1999;44(4):852-856.
4. Guédon C, Le Cam-Duchez V, Lalaude O, Ménard J, Lerebours E, Borg J. Prothrombotic inherited abnormalities other than factor V Leiden mutation do not play a role in venous thrombosis in inflammatory bowel disease. Am J Gastroenterol. 2001;96(5):1448-1454.
5. Koutroubakis I, Petinaki E, Anagnostopoulou E, et al. Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease. Dig Dis Sci. 1998;43(11):2507-2512.
6. Papa A, Danese S, Grillo A, Gasbarrini G, Gasbarrini A. Review article: inherited thrombophilia in inflammatory bowel disease. Am J Gastroenterol. 2003;98(6):1247-1251.
7. Koutroubakis I, Malliaraki N, Vardas E, et al. Increased levels of lipoprotein (a) in Crohn's disease: a relation to thrombosis? Eur J Gastroenterol Hepatol. 2001;13(12):1415-1419.
8. Bernstein C, Blanchard J, Houston D, Wajada A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost. 2001;85(3):430-434.
9. Vecchi M, Sacchi E, Saibeni S, et al. Inflammatory bowel diseases are not associated with major hereditary conditions predisposing to thrombosis. Dig Dis Sci. 2000;45(7):1465-1469.
10. Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut. 2004;53(4):542-548.
11. Solem C, Loftus E, Tremaine W, Sandborn W. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol. 2004;99(1):97-101.
12. Mahmud N, Molloy A, McPartin J, et al. Increased prevalence of methylenetetrahydrofolate reductase C677T variant in patients with inflammatory bowel disease, and its clinical implications. Gut. 1999;45(3):389-394.
13. Morgenstern I, Raijmakers M, Peters W, Hoensch H, Kirch W. Homocysteine, cysteine, and glutathione in human colonic mucosa: elevated levels of homocysteine in patients with inflammatory bowel disease. Dig Dis Sci. 2003;48(10):2083-2090.
14. Battaglioli T, Martinelli I. Hormone therapy and thromboembolic disease. Curr Opin Hematol. 2007;14(5):488-493.
15. Severinsen M, Kristensen S, Johnsen S, Dethlefsen C, Tjønneland A, Overvad K. Smoking and venous thromboembolism: a Danish follow-up study. J Thromb Haemost. 2009;7(8):1297-1303.
16. Kearon C, Kahn S, Agnelli G, et al; American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):454S-545S.
17. Lee A, Levine M, Baker R, et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-153.
18. Douketis J, Foster G, Crowther M, Prins M, Ginsberg J. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Int Med. 2000;160(22):3431-3436.
19. Douketis J, Crowther M, Foster G, Ginsberg J. Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis? Am J Med. 2001;110(7):515-519.
20. Rondina M, Pendleton R, Wheeler M, Rodgers G. The treatment of venous thromboembolism in special populations. Thromb Res. 2007;119(4):391-402.
21. Luk C, Wells P, Anderson D, Kovacs M. Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Am J Med. 2001;111(4):270-273.
22. Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982;307(27):1676-1691.
23. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med. 1998;338(7):409-415.
24. PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005;112(3):416-422.
25. Crowther M. Inferior vena cava filters in the management of venous thromboembolism. Am J Med. 2007;120(10 suppl 2):S13-S17.
26. Gellatly R. Intravenous warfarin as an alternative for anticoagulation. Pharmacotherapy. 2007;27(6):933-935.
27. Zikria J, Ansell J. Oral anticoagulation with Factor Xa and thrombin inhibitors: Is there an alternative to warfarin? Discov Med. 2009;8(43):196-203.
28. Osinbowale O, Ali L, Chi YW. Venous thromboembolism: a clinical review. Postgrad Med. 2010;122(2):54-65.